Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...

Pfizer will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon, lowering its stake in the British consumer ...

To further refine risk stratification, other mental health conditions or diagnostic tools should be considered, according to ...

Pfizer Inc. sold about 700 million shares in Haleon Plc, further paring its stake in the maker of Sensodyne toothpaste.Most ...

Pfizer divests $3.05 billion of Haleon shares, cutting its stake to 7.3% in a strategic shift to refocus on core ...

These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock.

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 could turn out.

Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate ...

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

The flu vaccine is generally about 40% effective at completely preventing influenza, according to Blumberg. The flu vaccine ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.